Healthcare >> Analyst Interviews >> October 17, 2011
Biotechnology Catalysts In A More Mature Stage – Steven Silver – Capital Iq
Steven Silver joined the U.S. equity research team at Standard & Poor's Capital IQ in July 2006. He is a Senior Industry Equity Analyst in the health care group covering the biotechnology and health care facilities sectors. Since assuming sector coverage, Mr. Silver has been quoted in several financial and trade publications, and his commentary has been featured by many media outlets, including Businessweek, CNBC and Reuters. Mr. Silver previously worked as a Fund Manager and Industry Analyst for the Nittany Lion Fund, LLC, primarily covering the information technology and utilities sectors. Previously, he spent five years providing investor relations consulting services. Mr. Silver has an MBA from Pennsylvania State University with a primary concentration in investment management and portfolio analysis. Profile
TWST: Where do you focus your attention in the biotech space these days?
Mr. Silver: I am an S&P Capital IQ Equity Analyst. I have no affiliation with any company we might talk about this